Clinical trials
Completed Neuralgia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
522 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 7 |
| 2003 | 8 |
| 2004 | 7 |
| 2005 | 14 |
| 2006 | 23 |
| 2007 | 20 |
| 2008 | 19 |
| 2009 | 17 |
| 2010 | 25 |
| 2011 | 32 |
| 2012 | 24 |
| 2013 | 20 |
| 2014 | 25 |
| 2015 | 17 |
| 2016 | 27 |
| 2017 | 23 |
| 2018 | 29 |
| 2019 | 26 |
| 2020 | 22 |
| 2021 | 26 |
| 2022 | 37 |
| 2023 | 27 |
| 2024 | 19 |
| 2025 | 13 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 522 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 20 |
| University Hospital, Clermont-Ferrand | 11 |
| Rigshospitalet, Denmark | 10 |
| Danish Pain Research Center | 9 |
| GlaxoSmithKline | 8 |
| NeurogesX | 8 |
| University of Sao Paulo | 8 |
| Barts & The London NHS Trust | 5 |
| Grünenthal GmbH | 5 |
| University of British Columbia | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuralgia | 522 |
| Pain | 96 |
| Chronic Pain | 77 |
| Neuralgia, Postherpetic | 36 |
| Spinal Cord Injuries | 35 |
| Diabetic Neuropathies | 33 |
| Postoperative Pain | 26 |
| Peripheral Nervous System Diseases | 24 |
| Low Back Pain | 22 |
| Diabetes Mellitus | 20 |
Trials
Showing 1 to 25 of 522. Each trial links to its page on Pharma Observatory.
422 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.